New single cell and spatial products set to
deliver higher performance, improve ease of use and enable
researchers to measure more biology
PLEASANTON, Calif., Feb. 5, 2024
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in
single cell and spatial biology, announced today a series of new
products and technology demonstrations that will be presented at
the 2024 Advances in Genome Biology and Technology (AGBT) General
Meeting this week in Orlando,
Florida.
"The new products we have planned for 2024 will take 10x to the
next level, as we deliver game-changing new technologies that will
redefine the Visium, Xenium and Chromium platforms," said
Ben Hindson, Co-founder and Chief
Scientific Officer of 10x Genomics. "Our team continues to raise
the bar for researchers, developing cutting-edge technologies that
'just work' and creating incredible single cell and spatial tools
to enable mind-blowing scientific discoveries."
10x Genomics will host a workshop at AGBT on Wednesday, February 7, at 1:10 p.m. ET to share the latest data and
development directions across its three platforms. This workshop
will be live-streamed for researchers not attending AGBT.
Visium Spatial Analysis
10x Genomics recently announced the launch of Visium HD, a
new product that enables whole transcriptome spatial discovery at
single-cell scale resolution. At AGBT, the company will share new
data to highlight the performance advantages of Visium HD, which is
now available for pre-order and is expected to start shipping this
quarter.
"Visium HD will be a powerful tool for spatial discovery,
empowering scientists to study the organization and interactions of
cells in real-world tissue samples with a high degree of detail
across the whole transcriptome," added Hindson. "The resolution
opens up the possibility to disaggregate what is happening within
niches and discover patterns and pathways in fine structures,
offering a complete view of the transcriptome with spatial
context."
Xenium In Situ Analysis
In its first full year of launch, the company's Xenium In
Situ platform has seen rapid growth and adoption, with more than
250 Xenium instruments sold and multiple independent benchmarking
studies demonstrating Xenium is the best performing platform for in
situ analysis.
At AGBT, 10x will share the latest data from the company's
comprehensive Xenium product roadmap, including:
- Multimodal cell segmentation, a new add-on kit compatible with
existing Xenium reagents to enable improved biological
interpretation, which is expected to begin shipping in Q1
2024.
- Xenium 5,000-plex panel, which delivers a massive codebook
expansion while maintaining the platform's high specificity,
per-gene sensitivity and throughput. The new 5,000-plex kit, which
can analyze 4 cm2 of tissue in six days, is expected to
start shipping in Q2 2024.
- Integrated Xenium Protein Profiling, a new assay expected in
the second half of the year, which will enable multiplex protein
detection and gene expression analysis on the same tissue section
in a single run.
Chromium Single Cell Analysis
At AGBT, 10x Genomics will unveil new products, features
and protocols designed to enable researchers with improved and more
cost effective single cell workflows.
10x Genomics will share new capabilities for its Chromium Flex
assay, including:
- Whole blood fixation to directly fix whole blood for storage
and later use with the Flex assay.
- Intracellular protein profiling to simultaneously analyze gene
expression and intracellular proteins including cytokines and
phospho-proteins.
- CRISPR/sgRNA screens to enable functional genetic screens at
scale and low cost.
At its Sponsor Workshop, 10x Genomics will also unveil major
product updates and new capabilities for its flagship Single Cell
Gene Expression and Single Cell Immune Profiling assays.
Posters and Featured Talks
Throughout AGBT, 10x Genomics will demonstrate the use of its
platforms to generate groundbreaking biological insights:
- Sponsor Workshop: Mind blowing science enabled by
industry-leading single cell & spatial technologies
(February 7, 2024). Register for the
livestream here.
- Featured Posters:
- Poster 301: A blood collection workflow for interrogation of
translational samples with single-cell technologies
- Poster 537: Cell boundary segmentation for the Xenium
Analyzer
- Poster 583: In situ detection and subcellular localization of
5,000 genes using Xenium Analyzer
- Poster 626: Scaling high-throughput, multimodal single cell
CRISPR screens using 10x Genomics Chromium Single Cell Gene
Expression Flex
- Poster 654: Visium HD enables whole-transcriptome spatial
profiling at single cell scale resolution in formalin-fixed,
paraffin embedded (FFPE) tissues
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with us on
LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s ("10x Genomics") product launches, performance,
configuration, capabilities and adoption. These statements are
based on management's current expectations, forecasts, beliefs,
assumptions and information currently available to management, and
actual outcomes and results could differ materially from these
statements due to a number of factors. Other risks and
uncertainties that could affect 10x Genomics' financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics files with the Securities and Exchange Commission (the
"SEC") from time to time. Although 10x Genomics believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-showcase-new-cutting-edge-technologies-and-highlight-innovation-roadmap-at-2024-agbt-general-meeting-302053701.html
SOURCE 10x Genomics, Inc